rs76763715 — GBA N409S

GBA N409S — The Lysosomal Gateway to Parkinson's Disease

Inside every cell, lysosomes act as the cellular recycling plant, breaking down worn-out proteins and glycolipids. Glucocerebrosidase (GCase)¹¹ Glucocerebrosidase (GCase)
the enzyme encoded by GBA1, converts the glycolipid glucosylceramide into glucose and ceramide — a routine metabolic step in the lysosomal pathway that turns out to have profound consequences for brain health. The p.Asn409Ser variant (formerly called N370S in older nomenclature) is the most common pathogenic GBA allele worldwide — and the most common genetic risk factor for Parkinson's disease discovered to date.

When one copy of this variant is inherited, glucocerebrosidase activity drops significantly but enough function remains to prevent overt disease. The catch: reduced GCase activity disrupts lysosomal autophagy — the cell's system for clearing misfolded proteins. Alpha-synuclein, the protein that aggregates into Lewy bodies in Parkinson's disease, depends on this pathway for its degradation. When the pathway is impaired, alpha-synuclein accumulates, forms toxic oligomers, and seeds neurodegeneration.

The Mechanism

p.Asn409Ser is a missense substitution in exon 9 of GBA1 at chromosomal position 1q22 (GRCh38 chr1:155235843). Because GBA is transcribed from the minus strand, the plus-strand T→C change corresponds to the coding-strand A→G transition (c.1226A>G), replacing asparagine with serine at protein position 409. This substitution alters the folding of glucocerebrosidase in the endoplasmic reticulum, triggering retention and premature degradation before the enzyme reaches the lysosome. The consequence: reduced lysosomal GCase activity and compensatory accumulation of glucosylceramide²² reduced lysosomal GCase activity and compensatory accumulation of glucosylceramide
Woodard et al. Stem Cell Rep 2014 in dopaminergic neurons.

The glucosylceramide buildup creates a bidirectional vicious cycle: elevated glucosylceramide stabilises alpha-synuclein oligomers, which in turn further inhibit GCase, deepening the lysosomal defect. Functional iPSC studies confirm that GBA N409S neurons produce significantly more alpha-synuclein protein and form aggregates more readily than wild-type neurons.

The Evidence

Parkinson's disease. The landmark multicenter study³³ The landmark multicenter study
Sidransky et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. NEJM, 2009 analyzed 5,691 PD patients and 4,898 controls across 16 international centers and found an overall OR of 5.43 for any GBA mutation. N409S-specific ORs from independent studies range from 3.08 to 3.96. Ashkenazi Jewish individuals — where N409S reaches ~2.9% allele frequency — show particularly high prevalence: 15% of Ashkenazi Jewish PD patients carry N370S or L444P, versus 3% of controls.

REM sleep behavior disorder. The largest RBD GWAS⁴⁴ The largest RBD GWAS
Krohn et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nat Commun, 2022 meta-analyzed ~2,843 cases and ~139,636 controls, identifying rs76763715-C (the N409S allele) as the variant with the largest effect size in the entire study: OR=2.84 (95% CI 2.06–3.92, p=2×10⁻¹⁰). REM sleep behavior disorder is recognized as the earliest detectable clinical sign of the alpha-synucleinopathy continuum — typically preceding PD diagnosis by 10–15 years.

Lewy body dementia. GBA N409S is also an established risk factor for dementia with Lewy bodies (DLB), consistent with the shared lysosomal and alpha-synuclein pathology across the synucleinopathy spectrum.

Gaucher disease. In the rare (~0.0004% of the general population) CC homozygous state, p.Asn409Ser abolishes sufficient GCase activity to cause Gaucher disease type I⁵⁵ Gaucher disease type I
the most common lysosomal storage disorder, characterized by hepatosplenomegaly, bone disease, and cytopenias but typically not neurological involvement — distinguishing it from types II/III. Heterozygous carriers do not develop Gaucher disease.

Practical Actions

For heterozygous CT carriers, the priority is supporting lysosomal function and alpha-synuclein clearance. Compounds that enhance GCase activity or promote autophagy-mediated protein clearance are the most mechanistically rational interventions. Prospective clinical trials in GBA-PD are ongoing; in the meantime, the lysosomal pathway provides specific, genotype-grounded targets distinct from generic neuroprotection advice.

Clinical monitoring matters here: RBD is detectable years before motor PD symptoms, and knowing your GBA status allows targeted screening. A sleep study (polysomnography) to evaluate for subclinical RBD, combined with a neurological assessment of smell and autonomic function, can capture prodromal synucleinopathy features at an actionable stage.

Interactions

rs76763715 and rs12752133 are independent GBA signals identified in the Krohn 2022 RBD GWAS — both at the GBA locus but at different positions (rs12752133 is intronic at chr1:155235587). Carrying risk alleles at both variants may further compound lysosomal and alpha-synuclein pathology, and the two are compound action candidates. In the broader synucleinopathy picture, GBA N409S is the largest known genetic contributor to risk across the full spectrum: RBD, PD, DLB, and GBA-related neurodegeneration all converge on the same lysosomal-autophagy mechanism.

GBA status also interacts with SNCA variants (rs356219, rs356182, rs2736990) in determining overall synucleinopathy risk — individuals carrying both a GBA risk allele and an SNCA risk allele face compounding lysosomal impairment and elevated alpha-synuclein substrate simultaneously.